Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
296
resultados
Última actualización
16/07/2026 [08:07:00]
Resultados 25 a 50 de 296
Resumen de: US20260183364A1
The present disclosure relates to methods for treating or alleviating a fetal alcohol spectrum disorder (FASD) in a subject, the method comprising administering to the subject an effective amount of an apolipoprotein E (APOE)-modulating therapeutic, thereby treating or alleviating the FASD.
Resumen de: JP2026110170A
【課題】本発明者らは、特に老化組織において炎症を抑制し得る素材をスクリーニングする技術の提供を主な目的とした。【解決手段】上記課題は、工程Ｂ：１５回以上継代された血管内皮細胞に被験物質を接触させる工程、並びに工程Ｃ：ＩＬ－６、ＩＬ－８、ＣＸＣＬ１、ＰＡＩ－１、ＭＭＰ－１、ＩＣＡＭ－１、ＶＣＡＭ－１、Ｅ－ｓｅｌｅｃｔｉｎ、及びＣＣＬ２からなる群より選択される少なくとも１種の炎症関連因子の、工程Ｂで被験物質を接触させた血管内皮細胞における発現量を評価する工程を含む方法により、解決され得る。【選択図】なし
Resumen de: WO2026142185A1
In a surface-enhanced Raman scattering-based method for testing drug reactivity of cerebrovascular cells, a SERS substrate is manufactured. A SERS substrate array including a plurality of the SERS substrates is manufactured. Cells are cultured on the SERS substrate array. A drug is administered to the cultured cells. A Raman signal is measured from the cells to which the drug is administered. An optimal drug is selected from among the administered drugs on the basis of the measured Raman signal.
Resumen de: WO2026142290A1
The present invention relates to a biomarker-specific binding probe and a use thereof. By introducing the probe into a nanopore, it is possible to accurately and rapidly detect the presence and abundance of a specific biomarker in a sample.
Resumen de: US20260186004A1
0000 It has been established that increased levels of lactylated of tau protein in the brain and CNS is associated with tauopathies and neurodegenerative diseases, and increased levels of lactylated lysine on tau protein has been established as a marked for AD. Compositions and methods for the detection and treatments of tauopathies have been developed. In some forms, the methods identify and quantify lactylated lysine on tau protein in a biological sample from a subject to diagnose a tauopathy, such as AD. In some forms, the methods identify a subject as having or at risk of having a tauopathy. In some forms, the methods include treating the tauopathy. Compositions to identify a tauopathy include lactylated tau binders, such as antibodies are also described. Compositions to treat or prevent a tauopathy, such as lactylated tau peptides having a defined lactyllysine, are also described.
Resumen de: US20260184770A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: WO2026141950A1
The present application provides: a spectroscopic analysis substrate for diagnosing dementia, comprising a hydrophilized graphene layer; and a spectroscopic device comprising same. More specifically, the present application provides: a spectroscopic analysis substrate for diagnosing dementia, having improved accuracy due to increased binding force and selectivity for amyloid beta, the substrate comprising a hydrophilized graphene layer; and a spectroscopic device comprising the spectroscopic analysis substrate.
Resumen de: WO2018218193A1
The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.
Resumen de: KR20260101594A
본원은 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다. 더욱 상세하게, 본원은 아밀로이드 베타와의 결합력 및 선택성 증가로 정확도가 개선된 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다.
Resumen de: CN121263693A
Provided herein are methods for detecting proteins and/or protein variants thereof, the methods comprising adding to a biological sample one or more small molecules and one or more protein binding agents wherein a protein crown is formed on a surface of the protein binding agent, and detecting the protein and/or protein variants thereof in the protein crown by antibody-based technology or proteomic technology. Also provided herein are methods for detecting one or more biomarkers or patterns of one or more biomarkers associated with a disease or health profile condition, as well as methods of diagnosing or predicting a disease in a subject. Compositions comprising one or more small molecules, one or more protein binding agents, and one or more biological samples are also provided.
Resumen de: US12668835B1
A sample holder includes a first member featuring a first retaining mechanism configured to retain a first substrate that includes a sample, a second member featuring a second retaining mechanism configured to retain a second substrate that includes a reagent medium, and an alignment mechanism connected to at least one of the first and second members, and configured to align the first and second members such that the sample contacts at least a portion of the reagent medium when the first and second members are aligned.
Resumen de: AU2020258381A1
Disclosed herein are methods for detecting a biological or chemical entity in a sample, wherein the biological or chemical entity is associated with extracellular vesicles. The methods disclosed comprise the steps of a) processing the sample, (b) using a detection assay to detect the presence of extracellular vesicles and to isolate the extracellular vesicles, (c) processing the extracellular vesicles to expose or release the biological or chemical entity, and (e) detecting the biological or chemical entity released from the extracellular vesicle. In certain embodiments, the extracellular vesicles are associated with proteins, glycoproteins, peptides, lipids, nucleic acids or other cellular components. The detection methods are useful for identifying the presence of microbial antigens related to
Resumen de: EP4560314A1
0001 The present invention relates to an ex vivo method for mapping the spatiotemporal electrophysiological dynamics and spatial transcriptional profiles of cells in a functional neuronal cell assembly, comprising simultaneous recording and analysis of spatial data of molecular and electrical network activity down to the level of individual cells using high-density electrical biosensors, spatial transcriptomics, optical imaging, and advanced computational strategies. The invention further relates to methods for identifying the composition of a functional neuronal assembly, for monitoring the spatiotemporal electrophysiological dynamics and transcriptional profiles of cells in a functional neuronal cell assembly, for monitoring the cellular composition of a functional neuronal assembly, or for identifying a compound having an effect on the spatial electrophysiological and transcriptional dynamics and/or for identifying the composition of cells in a functional neuronal cell assembly based on the dynamics as detected, as well as devices and uses thereof. The invention allows for a better understanding of disease mechanisms, and to find therapeutic targets and to develop new drugs and treatments.
Resumen de: CN122283142A
本发明公开了一种用于阿尔茨海默病早期筛查的泪液检测装置及方法，属于体外诊断医疗器械技术领域，包括泪液采样器、微流控芯片和便携式读数器，泪液采样器用于将采集并预处理的泪液样本输送至微流控芯片，微流控芯片上设置有样品输入口，泪液采样器与样品输入口连接，微流控芯片上设置有用于检测生物标志物的微通道结构，且微流控芯片能置于便携式读数器的卡槽内，便携式读数器用于进行信号检测并对监测数据进行分析后输出诊断结果。本发明采用上述的一种用于阿尔茨海默病早期筛查的泪液检测装置及方法，旨在实现阿尔茨海默病的早期、快速、高灵敏度诊断。
Resumen de: CN122283145A
本发明属于检测技术领域，本发明具体公开了一种磷酸化Tau181蛋白测定试剂盒及应用，本申请所述的抗试剂A和抗试剂B中的p‑Tau181抗体中的生物素和碱性磷酸酶发生反应，形成抗体‑抗原‑抗体复合物并通过生物素与链霉亲和素的反应结合到磁性微粒上，加入化学发光底物AMPPD，碱性磷酸酶催化AMPPD产生化学发光信号，通过光学检测系统测量发光强度，仪器自动通过工作曲线计算得出检测结果，本申请通过对试剂盒的抗试剂A和抗试剂B以及磁微粒试剂进行设计，能够精准捕获抗体并放大信号，有效的降低检测限，提升试剂盒的综合性能。
Resumen de: CN122282992A
本发明提供了一种测定人血浆中β‑淀粉样蛋白42/40比率的质谱方法，包括采用¹5N稳定同位素标记的完整Aβ42和Aβ40蛋白作为内标，通过免疫沉淀技术对血浆样本进行提取与纯化，并利用Lys‑N蛋白酶解产生特征性肽段，最终通过液相色谱‑串联质谱进行靶向定量分析。Aβ42的特征肽段是Aβ28‑42 KGAIIGLMVGGVVIA；Aβ40的特征肽段是Aβ28‑40 KGAIIGLMVGGVV。相较于完整蛋白，本发明中的特征肽段不易发生聚集且在质谱中具有更高的电离效率，展现出优异的特异性、重复性与灵敏度，能够为阿尔茨海默症的诊断提供可靠依据。
Resumen de: CN122291031A
0001 本发明公开了一种基于不良结局路径模型的污染物联合暴露毒性风险预警方法，建立联合暴露体系，将受试对象分为空白对照组、单一污染物暴露组及联合暴露组，在预设环境条件下进行暴露；在暴露过程中设置两个采样时间点，包括第一采样时间点和第二采样时间点；获取受试对象多层级检测指标数据，包括生化指标、组织病理指标、表面超微结构指标和/或基因表达指标；基于所述多层级检测指标数据，识别不良结局路径中的分子起始事件、早期关键事件、后期关键事件及不良结局，建立分子起始事件至关键事件再至不良结局的因果关联链条；根据不良结局的出现情况，输出分级风险预警结果。联合暴露体系中的受试对象为鱼类，污染物为全氟辛酸和聚苯乙烯微塑料。
Resumen de: CN122277725A
本申请实施例提供了一种抗NFL蛋白的单克隆抗体组合及其用途。所述单克隆抗体组合包括第一抗体和第二抗体，第一抗体包括第一重链可变区和第一轻链可变区，第二抗体包括第二重链可变区和第二轻链可变区；第一重链可变区包括如SEQ ID NO:3‑5所示的三个互补决定区，第一轻链可变区包括如SEQ ID NO:6‑8所示的三个互补决定区；第二重链可变区包括如SEQ ID NO:11‑13所示的三个互补决定区；第二轻链可变区包括如SEQ ID NO:14‑16所示的三个互补决定区。本实施例提供的单克隆抗体组合具有优异的特异性和高亲和力，可用于体外定量检测血清中NFL浓度，为神经系统相关疾病的辅助诊断提供技术支持。
Resumen de: CN122283146A
0001 本发明提供了人源卵泡抑素样蛋白（FSTL1）作为特发性正常压力脑积水标记物的应用及检测方法及试剂盒，其中，人源卵泡抑素样蛋白（FSTL1）的NCBI Gene ID 11167，RefSeq mRNA编号为NM_007085.5，RefSeq蛋白编码为NP_009016.1，UniProt编号为Q12841。本发明解决了现有检测技术中存在的无法早期分子识别、标志物特异性不足、低丰度蛋白检测灵敏度不足的技术问题。
Resumen de: CN122283116A
本发明公开了一种神经轻链蛋白的检测试剂盒、方法及磁性水凝胶制备方法，本发明的检测试剂盒，包含磁性水凝胶偶联探针，神经轻链蛋白检测抗体，预激发液和激发液；其中，磁性水凝胶偶联探针为表面络合有顺磁性的纳米四氧化三铁粒子的含羧基聚合物球形颗粒。
Resumen de: CN122277723A
0001 本发明公开了检测载脂蛋白E4的抗体及其应用，具体涉及检测阿尔茨海默症血液标志物ApoE4的检测抗体和试剂盒，基于该抗体及试剂盒能够准确的检测载脂蛋白E4的存在。
Resumen de: US20260176652A1
0000 In certain embodiments the present invention provides a method of treating hearing loss comprising: (a) administering a gene suppression agent that suppresses both copies of an endogenous gene causing the hearing loss; and (b) administering an exogenous wild-type allele engineered to resist suppression by the gene suppression agent. 0000 The present invention provides in certain embodiments a method of treating a genetic hearing loss (GHL) in a patient in need thereof comprising: (a) identifying a mutation in a GHL-causing gene, wherein the mutation causes GHL in the patient; and (b) administering to the patient a pharmaceutical composition comprising a therapeutic miRNA and a pharmaceutically acceptable carrier, wherein the GHL therapeutic miRNA is of 18 to 25 nucleotides in length and knocks-down the GHL-causing gene function at a higher level than it knocks-down gene function in a corresponding wild-type gene.
Resumen de: US20260177567A1
The present invention comprises a method for determining the biological age of an animal, wherein the method comprises determining the level of at least one biomarker in said animal, and wherein the at least 1 biomarker is selected from the biomarkers as listed in Table 1.
Resumen de: AU2024406255A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Nº publicación: US20260177560A1 25/06/2026
Solicitante:
GRYPHON BIO INC [US]
GRYPHON BIO, INC.
Resumen de: US20260177560A1
A process for determining an extent of a central nervous system (CNS) specific neurological condition in a subject including collecting a biological sample of biofluid from the subject and measuring a quantity of a first biomarker, or metabolite of or mRNA corresponding to, the first biomarker from the sample from a dried spot or through a microfluidic device. The biofluid is capillary blood or saliva, which affords ease of collection advantages that are attractive for field-, hospital-, and home-based environments. The process being useful in the diagnosis, care, and management of brain specific abnormal neurological conditions in general, and in particular, to traumatic brain injury (TBI) and (TBI-induced) Alzheimer's disease (AD) and Alexander disease, in which a GFAP mutation is implicated in white matter deterioration.
BOPI
Sede Electrónica
